In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

The work further revealed how an MDM2-targeted therapy could turn the anticancer protein back on, thereby extending survival in model systems. The findings were published today in Cancer Cell. In a ...

KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors KT-253 is a highly potent and selective heterobifunctional degrader of the MDM2 ...

Subscribe for unlimited access. A subscription to European Rubber Journal includes: Every issue of European Rubber Journal (6 issues) including Special Reports & Maps. Unlimited access to ERJ articles ...